Aug 13, 2020
ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast Track Designation for Recurrent and Metastatic Cervical Cancer
Jun 22, 2020
Dracen announces two DRP-104 presentations at AACR
Jun 18, 2020
Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing
Jun 17, 2020
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
Jun 10, 2020
Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody
Jun 10, 2020
PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I
Jun 05, 2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
Jun 02, 2020
World Market for Next Generation Immune Checkpoint Inhibitors and Stimulators - Forecast and Opportunity Analysis
May 29, 2020
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
May 15, 2020
Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
May 15, 2020
BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development
May 13, 2020
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
May 12, 2020
Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
May 07, 2020
Mediolanum Farmaceutici Acquires the French Company ElsaLys Biotech to Develop Next Generation Immuno-oncology Therapies
Apr 24, 2020
Global Immune Checkpoint Modulators Market 2020 - Current and Emerging Key Products & Players, Main Unmet Needs, R&D Challenges, Strategies & Opportunities, Clinical Development Trends
Apr 23, 2020
SITC Announces Three Recipients of the 2020 Richard V. Smalley, MD, Memorial Award and Lectureship
Apr 15, 2020
Portage provides update on portfolio company, Intensity Therapeutics, Inc.
Feb 20, 2020
Biocare Medical Launches 7 Novel IVD Antibodies for Clinical Diagnostic and Cancer Research Applications with a Focus on Immuno-Oncology
Feb 20, 2020
Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody HMBD-002 for Cancer Clinical Trial